Praxis Precision Medicines
Praxis Precision Medicines offers drug development services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $150m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 250 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (5147 %) | (2336 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (5038 %) | (2137 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | - | 3546 % | 1782 % |
Source: Company filings or news article
Related Content
Praxis Precision Medicines is a clinical stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, particularly those characterized by neuronal imbalance. The company leverages insights from genetic epilepsies to create innovative treatments aimed at addressing unmet medical needs. Praxis operates in the biopharmaceutical market, primarily serving patients with CNS disorders and their caregivers. The business model revolves around patient-guided development strategies, ensuring that the therapies developed are aligned with what patients actually need. Revenue is generated through the development and potential commercialization of these therapies, as well as through partnerships and collaborations with other entities in the healthcare sector.
Keywords: CNS disorders, genetic epilepsies, biopharmaceutical, therapies, neuronal imbalance, patient-guided, clinical stage, innovation, healthcare, partnerships.